Journal of Cardiovascular Pharmacology:
Effect of Exogenous Kappa-Opioid Receptor Activation in Rat Model of Myocardial Infarction
Peart, Jason N. PhD; Gross, Eric R. BS, MS; Gross, Garrett J. PhD
From the Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Received for publication July 10, 2003; accepted November 21, 2003.
Supported by NIH Grant # HL08311. Jason N. Peart is a recipient of an AHA Postdoctoral Fellowship. Eric R. Gross is a recipient of an AHA Predoctoral Fellowship.
Reprints: Garrett J. Gross, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53222 (e-mail: firstname.lastname@example.org).
The involvement of opioid receptor activation during ischemia-reperfusion is somewhat controversial. While it is generally accepted that activation of the δ-opioid receptor (DOR) is cardioprotective, and may indeed be an important mediator of ischemic preconditioning, the role of the κ-opioid receptor (KOR) is less well understood. To this end, we examined three different KOR agonists and their effects upon infarct size and arrhythmia development. Male Sprague-Dawley rats were subjected to 30 minutes of occlusion followed by 90 minutes of reperfusion. Opioid receptor agonists were administered 10 minutes before the onset of ischemia, while the opioid antagonists were given 20 minutes before occlusion. Untreated rats exhibited an infarct size (IS/AAR%) of 52.4 ± 2.7%. Pretreatment with the DOR agonist, BW373U86, limited infarct development to 37.2 ± 1.8%, which was reversed by the selective DOR antagonist, BNTX. All three KOR agonists studied, U50,488, ICI 204,448, and BRL 52537 significantly reduced infarct size to levels comparable to that of BW373U86. The infarct-sparing effects of U50,488 and ICI 204,448 were abolished by the selective KOR antagonist, nor-BNI. Nor-BNI failed to inhibit the cardioprotective effects of BRL 52537. Furthermore, U50,488 and BRL 52537, but not ICI 204,448, significantly reduced the incidence of arrhythmias. These effects were not blocked by nor-BNI.
These data demonstrate that KOR activation provides a similar degree of infarct size reduction as DOR activation. KOR agonists also reduced arrhythmogenesis; however, these responses appear to be independent of KOR activation.
Myocardial binding studies demonstrate that κ- and δ-opioid receptors (KORs and DORs, respectively) are present on adult ventricular myocytes of rats and humans, 1,2 while μ-opioid receptors are absent.
Schultz et al 3 first reported that activation of opioid receptors may induce acute cardioprotection. Following these initial studies, exogenous opioids have been shown to afford cardioprotection against both stunning and infarction. 4,5 Similarly, it has been reported that endogenous opioids have a role in the triggering and maintenance of both early and delayed preconditioning against myocardial infarction.
Opioid antagonists, both non-selective and selective for the DOR, have been demonstrated to attenuate the cardioprotective effects of ischemic preconditioning (IPC) in both rat and rabbit hearts. 6,7 Moreover, subtype selective δ1 opioid receptor (D1OR) agonists have been shown to provide pronounced cardioprotective actions in both intact animals and isolated myocytes via activation of Gi/o proteins, protein kinase C, and the mitochondrial KATP channel. 5,8 The cardioprotective effects provided by DOR activation manifest immediately following receptor activation and reappear 24 to 48 hours posttreatment in rats and rabbits. 9,10
While it is generally accepted that DOR activation affords cardioprotection, data regarding the KOR are conflicting with many papers reporting cardioprotection from KOR activation while others report no effect or protection after KOR blockade. While KOR activation appears not to be involved in acute IPC, recent data suggest that activation of the KOR is indeed protective in an isolated rat model. 11 Furthermore, treatment with the KOR agonist U50,488 leads to a preconditioning-like effect in isolated myocytes. 12 However, Huh et al 13 showed no protection via KOR in isolated chick myocytes while Aitchison et al 14 demonstrated that stimulation of KOR augmented infarct development. Indeed the data provided by Aitchison et al are supported by several earlier reports examining the arrhythmogenic effects of KOR agonists in which these compounds were shown to exacerbate ischemia/reperfusion-induced arrhythmias while KOR antagonists were found to attenuate arrhythmogenesis. Furthermore, it has been suggested that some of the actions of KOR agonists are due to direct effects on ion channels, independent of KOR activation.
Therefore, in light of the controversies surrounding the effects of KOR activation in the ischemic myocardium, the goal of this study was to examine and compare the effects of 3 selective KOR agonists, U50,488, ICI 204,448, and BRL 53527, on infarct size and the incidence of arrhythmias in an intact rat model of myocardial infarction.
This study was performed in accordance with the guidelines of the Animal Care Committee of the Medical College of Wisconsin, which is accredited by the American Association of Laboratory Animal Care.
General Surgical Preparation
Male Sprague-Dawley rats weighing 250 to 350 g were used throughout this study. The rats were anesthetized via intraperitoneal administration of thiobutabarbital sodium (Inactin; 100 mg/kg). A tracheotomy was performed, and the trachea was intubated with a cannula connected to a rodent ventilator (model CIV-101, Columbus Instruments: Columbus, OH, or model 683, Harvard Apparatus: Natick, MA). The rats were ventilated with room air supplemented with 100% O2. Atelectasis was prevented by maintaining a positive end-expiratory pressure of 5 to 10 mm H2O. Arterial pH, PCO2, and PO2 were monitored throughout the protocol by a blood gas analyzer (AVL 995, pH/Blood gas analyzer) and maintained within a normal physiological range (pH, 7.35–7.45; PCO2, 25–40 mm Hg; and PO2, 80–110 mm Hg) by adjusting the respiratory rate and/or tidal volume. Body temperature was maintained at 37°C by the use of a heating pad.
The right carotid artery was cannulated with polyethylene tubing PE-50 to measure blood pressure and heart rate (HR) via a PE-23 (Gould) pressure transducer connected to a polygraph (model 7, Grass). The right jugular vein was cannulated for delivery of saline or drug infusion. A left thoracotomy was performed at the fifth intercostal space, followed by a pericardiotomy and adjustment of the left atrial appendage to reveal the location of the left coronary artery. A ligature (6-0 Prolene) was passed below the left descending vein and coronary artery from the area immediately below the left atrial appendage to the right portion of the LV. The ends of the suture were threaded through a propylene tube to form a snare. Occlusion of the coronary artery and subsequent regional LV ischemia was produced by pulling the ends of the suture taut and clamping the snare onto the epicardial surface with a hemostat. Epicardial cyanosis and a subsequent decrease in blood pressure verified coronary artery occlusion. Reperfusion of the heart was initiated via unclamping the hemostat and relieving tension from the snare and was confirmed by visualizing a marked epicardial hyperemic response. HR and blood pressure were allowed to stabilize before initiation of experimental protocols.
Determination of Infarct Size
On completion of the experimental protocols, the coronary artery was reoccluded, and the area at risk (AAR) was determined by negative staining. Patent blue dye was administered via the jugular vein to effectively stain the nonoccluded area of the LV. The heart was excised, and the LV was removed from the remaining tissue and subsequently cut into 5 thin cross-sectional pieces. This allowed for the delineation of the normal area, which stained blue, versus the AAR, which subsequently remained pink. The AAR was excised from the nonischemic area, and the tissues were placed in separate vials and incubated for 15 minutes in a 1% TTC solution in 100 mM phosphate buffer (pH 7.4) at 37°C. Tissues were stored in vials of 10% formaldehyde overnight and the infarcted myocardium was carefully dissected from the AAR by an independent observer under the illumination of a dissecting microscope (Cambridge Instruments). Infarct size (IS) and area at risk (AAR) were determined by gravimetric analysis. IS was expressed as a percentage of the AAR (IS/AAR).
Arrhythmic properties of various KOR agonists in the absence or presence of the KOR antagonist, nor-BNI, were also analyzed. Arrhythmias were quantitated via a modified scoring system previously validated by Curtis and Walker 15 in an in vivo model of ischemia. The scoring system employed assigned scores during ten 3-minute intervals of myocardial occlusion. Arrhythmias were scored as follows: 0 = < 10 premature ventricular contraction (PVCs)/3-minute period; 1 = 10 to 50 PCVs/3-minute period; 2 = > 50 PVCs/3-minute period; 3 = 1 episode of ventricular fibrillation (VF)/3-minute period; 4 = 2 to 5 episodes of VF/3-minute period, and 5 = > 4 episodes of VF/3-minute period.
Following equilibration of hemodynamic parameters, rats were divided into various experimental groups. Rats were either untreated, treated with agonist alone, antagonist alone, or treated with both agonists and antagonists. Agonists were given as a bolus dose 10 minutes before the onset of ischemia, whereas antagonists were given 20 minutes before ischemia. Following treatment, hearts were occluded for 30 minutes followed by 90 minutes of reperfusion before TTC staining. Since most previous studies concerning the cardioprotective effects of KOR stimulation were performed with U50,488, we included 2 additional KOR agonists to ascertain that other KOR agonists shared the cardioprotective effects previously demonstrated with U50,488. Thus, a peripherally active KOR agonist, ICI204,448, which does not cross the blood brain barrier, and a systemically active KOR agonist, BRL53527, which does cross the blood brain barrier, were used. In addition, the selective DOR agonist, BW373U86, was used for comparison purposes.
Rats were excluded from data analysis if they exhibited severe hypotension (<30 mm Hg systolic pressure) or if we were unable to maintain adequate blood gas values within a normal physiological range due to metabolic acidosis. Exclusion of animals from the present study was evenly distributed among protocol groups.
Statistical Analysis of Data
All values are expressed as mean ± SEM. One-way analysis of variance with Newman-Keuls post hoc test was used to determine whether any significant differences existed in any parameter between groups. Significant differences were determined at P < 0.05.
The hemodynamic data are summarized in Table 1. No differences from untreated rats were observed at baseline for any parameter. During the 30 minutes of coronary occlusion, both BW373U86 and ICI + nor-BNI treated groups displayed a significantly higher mean arterial pressure (MAP). At the completion of the reperfusion period, the BW373U86-treated rats still exhibited an elevated MAP, an effect that was not attenuated by the selective DOR-antagonist, BNTX.
No differences were noted in the ratio of left-ventricle mass to area at risk between groups. Activation of the DOR following pretreatment with 1 mg/kg BW373U86 markedly reduced infarct size from 52.4 ± 2.7% for untreated rats to 37.2 ± 1.8% (Fig. 1). This protection was completely reversed by 1 mg/kg of the selective δ1 opioid receptor antagonist, BNTX. BNTX alone had no effect on infarct size.
KOR activation with U50,488 (0.1 mg/kg), ICI 204,448 (0.3 mg/kg), and BRL 52537 (0.5 mg/kg) all significantly reduced infarct development to 38.5 ± 2.6%, 34.9 ± 3.1%, and 41.6 ± 1.7%, respectively (Fig. 2). Pretreatment with the selective KOR antagonist, nor-BNI (0.1 mg/kg), abolished the infarct-reducing effects of U50,488 and ICI 204,448; however, it failed to attenuate the infarct-sparing effect of BRL (37.3 ± 3.9%). Nor-BNI had no effect on infarct size when administered alone.
Incidence of Arrhythmias
Arrhythmia scores for the 30-minute occlusion period are presented in Figure 3. U50,488 and BRL 52537 significantly reduced the incidence of arrhythmias, while ICI 204,448 failed to exhibit an effect. Interestingly, nor-BNI failed to inhibit the anti-arrhythmic effect of either U50,488 or BRL 52537, which suggests that this effect of these two agonists is not mediated by the KOR.
The results of this study provide clear evidence that exogenous KOR activation provides protection against infarct development in an in vivo rat model. Indeed, the infarct-sparing ability of KOR activation was equal to that of DOR activation. Furthermore, our data demonstrate that U50,488 and BRL 52537 also produce a pronounced anti-arrhythmic effect. While previous studies have demonstrated anti-arrhythmic and infarct-reducing properties of KOR activation, 11,13,16,17 this is the first study to examine the effects of exogenous KOR activation by several structurally different KOR agonists on arrhythmias and infarct size in the same model.
In a previous study from our laboratory, we demonstrated a lack of involvement of the KOR in mediating ischemic preconditioning (IPC) in the intact rat. 18 While KOR activation may not be involved in the genesis of IPC, the disparity of the findings may have been due to the length of drug exposure to the KOR antagonist, nor-BNI. Nor-BNI exhibits slow binding kinetics to the KOR 19,20; thus the 15-minute incubation time used by Schultz et al may have been too short to allow thorough binding. Regardless, nor-BNI used at a dose similar to that which did not block IPC, did abolish the infarct-sparing effects of U50,488 and ICI 204,448 in this study. Interestingly, KOR blockade failed to inhibit the protection provided by BRL 52537. BRL 52537 is considered a highly selective KOR agonist without any preferential binding to putative KOR subtypes, 21 while nor-BNI may be a K1OR-selective antagonist. 19,22 Furthermore, nor-BNI failed to attenuate the anti-arrhythmic effect produced by BRL 52537. Thus, it appears that the effects of BRL 52537 may be independent of the KOR, or at least, insensitive to nor-BNI. Zhang et al 22 have provided evidence for 2 KOR subtypes in cardiac tissue, whereby one subtype is U50,488-sensitive and DADLE-insensitive, and one is U50488-insensitive and DADLE-sensitive. Thus, it is possible that BRL 52537 may be acting via the latter subtype that may be insensitive to nor-BNI.
Interestingly, the peripherally active KOR agonist ICI 204,448, 23,24 while displaying a pronounced infarct-limiting effect, failed to possess any effect upon arrhythmogenesis. This has been previously demonstrated in a similar model of coronary ligation, 25 even in the presence of a much higher dose of ICI 204,448 (5 mg/kg). Furthermore, McIntosh et al 25 demonstrated an anti-arrhythmic effect of nor-BNI at a dose of 2.5 mg/kg, but not at 0.5 mg/kg. Indeed, many previous studies have suggested a role for endogenous opioids in arrhythmogenesis during/following ischemia-reperfusion 26,27; however, this appears to occur at higher doses of the agonist/antagonist. At the dose of nor-BNI used in the present study (0.1 mg/kg) we failed to demonstrate an anti-arrhythmic effect of nor-BNI. Recently, a study by Yu et al 28 described pro- and anti-arrhythmic effects of the KOR agonist U50,488 at high and low concentrations respectively. Our findings show that U50,488 did indeed attenuate arrhythmogenesis; however, similar to results obtained with BRL 52537, nor-BNI failed to inhibit these antiarrhythmic effects. These data are supported by those of Pugsley et al 17 who also demonstrated that the antiarrhythmic effect of U50,488 was independent of opioid receptors since the non-selective opioid antagonist, naloxone, failed to antagonize the antiarrhythmic effect of U50,488 in a similar anesthetized model. Interestingly, it has been suggested that the primary antiarrhythmic effect of KOR agonists is not the result of KOR activation but from a direct effect on ion channels. Several lines of evidence support an ion channel-blocking property of KOR agonists that appears to be independent of KOR activation. U50,488, along with other KOR agonists, has been shown to prolong the P-R interval and QRS duration, along with inhibiting contractile function in isolated rat hearts, 29 suggesting that these agents may block Na+ and K+ channels. These effects were not blocked by naloxone. 29,30 KOR agonists may also antagonize l-type Ca2+ channels. 31 Indeed, the apparent receptor-independent antiarrhythmic actions of KOR agonists may be due to direct blockade of cardiac Na+, K+, or Ca2+ channels. 29,30,32
However, there is evidence to suggest that the KOR agonists may, indeed, elicit their actions on ion channels via the KOR. Alterations in the [Ca2+]i transient produced by U50,488 appears to be mediated via pertussis toxin-sensitive G proteins. 33,34 Analgesia induced by U50,488 appears to be mediated by pertussis-sensitive G proteins coupled to l-type Ca2+ channels. 35 Furthermore, the arrhythmogenic action of U50,488 coupled to a rise in [Na+]i and [Ca2+]i may be due to a protein kinase C/ Na+-H+ exchange pathway 36 and involves phospholipase C and inositol 1,4,5 triphosphate. 33,34 Indeed, a report by Zhang et al 37 suggests that Ca2+ channel blockers compete with KOR agonists in binding to the KOR in a dose-dependent manner.
Regardless, KOR blockade failed to inhibit the anti-arrhythmic actions of KOR agonists in our intact rat model. While nor-BNI failed to block the anti-arrhythmic effects of U50,488, blockade of the KOR negated the infarct-sparing actions of U50,488. These data are supported by those of Wang et al 11 as well as others. 38 However, a recent study by Aitchison et al 14 reported that KOR activation increased infarct size while DOR activation reduced infarct size in isolated rat hearts. The increase in infarct size observed by Aitchison was reversed by nor-BNI. However, the KOR agonist employed by Aitchinson, bremazocine, was shown to inhibit cyclic AMP accumulation, which was not attenuated by nor-BNI. 39 Furthermore, Coles et al 40 reported that the DOR agonist DADLE only provided protection against infarct development in swine when administered in the presence of nor-BNI. The variation between results reported by Coles et al and our findings may be explained by species and model differences. Indeed, the swine exhibit a lower metabolic rate than the rat and protection afforded by DADLE was not associated with alterations in the levels of high-energy phosphates in swine. 41
In summary, we provide evidence demonstrating the anti-arrhythmic and/or infarct-sparing actions of 3 KOR agonists. The infarct-limiting effect of the KOR agonists was as great as that provided by exogenous DOR activation. KOR blockade failed to modify the marked anti-arrhythmic actions of U50,488 and BRL 53527, which suggests that the anti-arrhythmic effect may be independent of KOR activation. However, these data provide evidence that use of KOR agonists may have beneficial clinical effects.
1. Bell SP, Sack MN, Patel A, et al. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol. 2000; 36:2296–2302.
2. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther. 200; 89:123–137.
3. Schultz JE, Rose E, Yao Z, et al. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol. 1995; 268:H2157–H2161.
4. Ross S, Munoz H, Piriou V, et al. A comparison of the effects of fentanyl and propofol on left ventricular contractility during myocardial stunning. Acta Anaesthesiol Scand. 1998; 42:23–31.
5. Schultz E, Hsu AK, Nagase H, et al. TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. Am J Physiol. 1998; 274:H909–H914.
6. Miki T, Cohen MV, Downey JM. Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem. 1998; 186:3–12.
7. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart. J Mol Cell Cardiol. 1997; 29:1355–1362.
8. Sigg DC, Coles JA, Gallagher WJ, et al. Opioid preconditioning: myocardial function and energy metabolism. Ann Thorac Surg. 2001; 72:1576–1582.
9. Fryer RM, Hsu AK, Eells JT, et al. Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res. 1999; 84:846–851.
10. Kodani E, Xuan YT, Shinmura K, et al. Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits. Am J Physiol Heart Circ Physiol. 2002; 283:H1943–H1957.
11. Wang GY, Wu S, Pei JM, et al. Kappa-but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. Am J Physiol Heart Circ Physiol. 2001; 280:H384–H391.
12. Zhou JJ, Pei JM, Wang GY, et al. Inducible HSP70 mediates delayed cardioprotection via U-50488H pretreatment in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2001; 281:H40–H47.
13. Huh J, Gross GJ, Nagase H, et al. Protection of cardiac myocytes via delta(1)-opioid receptors, protein kinase C, and mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol. 2001; 280:H377–H383.
14. Aitchison KA, Baxter GF, Awan MM, et al. Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning. Basic Res Cardiol. 2000; 95:1–10.
15. Curtis MJ, Walker MJ. Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. Cardiovasc Res. 1988; 22:656–665.
16. Valtchanova-Matchouganska A, Ojewole JA. Involvement of opioid delta- and kappa -receptors in ischemic preconditioning in a rat model of myocardial infarction. Methods Find Exp Clin Pharmacol. 2002; 24:139–144.
17. Pugsley MK, Penz WP, Walker MJ, et al. Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion. Eur J Pharmacol. 1992; 212:15–19.
18. Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1-but not mu- or kappa-opioid receptors. Circulation. 1998; 97:1282–1289.
19. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987; 40:1287–1292.
20. Birch PJ, Hayes AG, Sheehan MJ, et al. Norbinaltorphimine: antagonist profile at kappa opioid receptors. Eur J Pharmacol. 1987; 144:405–408.
21. Vecchietti V, Giordani A, Giardina G, et al. (2S)-1-(arylacetyl)-2-(aminomethyl)piperidine derivatives: novel, highly selective kappa opioid analgesics. J Med Chem. 1991; 34:397–403.
22. Zhang WM, Jin WQ, Wong TM. Multiplicity of kappa opioid receptor binding in the rat cardiac sarcolemma. J Mol Cell Cardiol. 1996; 28:1547–1554.
23. Shaw JS, Carroll JA, Alcock P, et al. ICI 204448: a kappa-opioid agonist with limited access to the CNS. Br J Pharmacol. 1989; 96:986–992.
24. Keita H, Kayser V, Guilbaud G. Antinociceptive effect of a kappa-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy. Eur J Pharmacol. 1995; 277:275–280.
25. McIntosh M, Kane K, Parratt J. Effects of selective opioid receptor agonists and antagonists during myocardial ischaemia. Eur J Pharmacol. 1992; 210:37–44.
26. Lee AY, Chen YT, Kan MN, et al. Consequences of opiate agonist and antagonist in myocardial ischaemia suggest a role of endogenous opioid peptides in ischaemic heart disease. Cardiovasc Res. 1992; 26:392–395.
27. Kan MN, Chen YT, Lee AY. Naloxone reversal of ischemic arrhythmia is stereospecific and suggests role of endogenous opioid peptides in ischemic heart disease. Proc Soc Exp Biol Med. 1992; 200:518–521.
28. Yu X, Zhang W, Bian J, et al. Pro- and anti-arrhythmic effects of a kappa opioid receptor agonist: a model for the biphasic action of a local hormone in the heart. Clin Exp Pharmacol Physiol. 1999; 26:842–844.
29. Pugsley MK, Saint DA, Penz MP, et al. Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289. Br J Pharmacol. 1993; 110:1579–1585.
30. Pugsley MK, Saint DA, Hayes ES, et al. Sodium channel-blocking properties of spiradoline, a kappa receptor agonist, are responsible for its antiarrhythmic action in the rat. J Cardiovasc Pharmacol. 1998; 32:863–874.
31. Kasper E, Ventura C, Ziman BD, et al. Effect of U-50,488H on the contractile response of cardiomyopathic hamster ventricular myocytes. Life Sci. 1992; 50:2029–2035.
32. Pugsley MK, Penz WP, Walker MJ, et al. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade. Br J Pharmacol. 1992; 105:521–526.
33. Sheng JZ, Wong NS, Wang HX, et al. Pertussis toxin, but not tyrosine kinase inhibitors, abolishes effects of U-50488H on [Ca2+]i in myocytes. Am J Physiol. 1997; 272:C560–C564.
34. Bian JS, Zhang WM, Xia Q, et al. Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart. J Mol Cell Cardiol. 1998; 30:2103–2110.
35. Gullapalli S, Ramarao P. Role of L-type Ca(2+) channels in pertussis toxin induced antagonism of U50,488H analgesia and hypothermia. Brain Res. 2002; 946:191–197.
36. Bian JS, Pei JM, Cheung CS, et al. kappa -opioid receptor stimulation induces arrhythmia in the isolated rat heart via the protein kinase C/Na(+)-H(+)exchange pathway. J Mol Cell Cardiol. 2000; 32:1415–1427.
37. Zhang WM, Wang HX, Xia Q, et al. Inhibition of [3H]-U69593 binding and the cardiac effects of U50, 488H by calcium channel blockers in the rat heart. Br J Pharmacol. 1997; 120:827–832.
38. Pyle WG, Smith TD, Hofmann PA. Cardioprotection with kappa-opioid receptor stimulation is associated with a slowing of cross-bridge cycling. Am J Physiol Heart Circ Physiol. 2000; 279:H1941–H1948.
39. Zhang WM, Wu S, Yu XC, et al. Effects of U50488 and bremazocine on [Ca2+]i and cAMP in naive and tolerant rat ventricular myocytes: evidence of kappa opioid receptor multiplicity in the heart. J Mol Cell Cardiol. 1999; 31:355–362.
40. Coles Jr, JA Sigg DC, Iaizzo PA. Role of kappa-opioid receptor activation in pharmacological preconditioning of swine. Am J Physiol Heart Circ Physiol. 2003; 284:H2091–H2099.
41. Sigg DC, Coles JA, Gallagher WJ, et al. Opioid preconditioning: myocardial function and energy metabolism. Ann Thorac Surg. 2001; 72:1576–1582.
This article has been cited 19 time(s).
Bulletin of Experimental Biology and Medicine
Cardioprotective effect of kappa(1)-Opioid receptor activation and role of cAMP in its realization
Bulletin of Experimental Biology and Medicine, 143(1):
Biology BulletinRole of kappa(1) opioid receptors and cAMP in regulation of cardiac tolerance to ischemia and reperfusionBiology Bulletin
Current Therapeutic Research-Clinical and ExperimentalPreconditioning effects of on myocardial ischemia/reperfusion injury in ratsCurrent Therapeutic Research-Clinical and Experimental
Archives of Medical ResearchAnti-arrhythmic effects of kappa-opioid receptor and its changes in ischemia and reperfusionArchives of Medical Research
Experimental Biology and Medicine
Vagotonic effects of enkephalin are not mediated by sympatholytic mechanisms
Experimental Biology and Medicine, 231(4):
Journal of Comparative Physiology B-Biochemical Systemic and Environmental PhysiologyIdentification of qRT-PCR reference genes for analysis of opioid gene expression in a hibernatorJournal of Comparative Physiology B-Biochemical Systemic and Environmental Physiology
American Journal of Physiology-Heart and Circulatory PhysiologyEvidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activationAmerican Journal of Physiology-Heart and Circulatory Physiology
Cardiovascular ResearchAdenosine-mediated cardioprotection in the aging myocardiumCardiovascular Research
Biology BulletinEffects of activation of mu-, kappa(1)-, delta(1)-, delta(2)-, and ORL1-receptors on heart resistance to the pathogenic action of delayed ischemia and reperfusionBiology Bulletin
Scandinavian Cardiovascular JournalDelayed uncoupling is related to cardioprotection induced by kappa-agonist U-50,488H in rat heartScandinavian Cardiovascular Journal
Heart and VesselsCardioprotective and antiarrhythmic effect of U50,488H in ischemia/reperfusion rat heartHeart and Vessels
Basic Research in CardiologyGSK3 beta inhibition and K-ATP channel opening mediate acute opioid-induced cardioprotection at reperfusionBasic Research in Cardiology
PeptidesEndogenous opiates and behavior: 2004Peptides
Bulletin of Experimental Biology and Medicine
Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists
Bulletin of Experimental Biology and Medicine, 145(6):
Basic Research in CardiologyActivation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse heartsBasic Research in Cardiology
Biology BulletinRole of kappa(1) opioid receptors and cAMP in regulation of cardiac tolerance to ischemia and reperfusionBiology Bulletin
Bulletin of Experimental Biology and Medicine
Role of Intracellular Calcium and Cyclic Nucleotides in Realization of Cardioprotective Effects of delta(1)- and kappa(1)-Opioid Receptor Agonists
Bulletin of Experimental Biology and Medicine, 148(6):
Life SciencesRole of endogenous opioid peptides in the infarct size-limiting effect of adaptation to chronic continuous hypoxiaLife Sciences
Journal of Cardiovascular PharmacologyPreconditioning Effects of Levosimendan in a Rabbit Cardiac Ischemia-Reperfusion ModelJournal of Cardiovascular Pharmacology
arrhythmia; infarction; in vivo rat; kappa-opioid receptor
© 2004 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.